Skip to main content
. 2022 Dec 5;14(12):2721. doi: 10.3390/pharmaceutics14122721

Figure 2.

Figure 2

USD spent until 2019 on biosimilars; Graphs indicating (a) molecules with no launched biosimilars versus USD spent till 2019 on biosimilars and (b) molecules with launched biosimilars versus USD spent till 2019 on biosimilars [22].